Structure of Valdecoxib
CAS No.: 181695-72-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Valdecoxib is a potent COX inhbitor that selectively inhibitors COX-2 with IC50 of 5 nM.
Synonyms: SC 65872
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 181695-72-7 |
Formula : | C16H14N2O3S |
M.W : | 314.36 |
SMILES Code : | O=S(C1=CC=C(C2=C(C)ON=C2C3=CC=CC=C3)C=C1)(N)=O |
Synonyms : |
SC 65872
|
MDL No. : | MFCD00950568 |
InChI Key : | LNPDTQAFDNKSHK-UHFFFAOYSA-N |
Pubchem ID : | 119607 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H332-H335 |
Precautionary Statements: | P280-P305+P351+P338-P310 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
Human platelets | 0–100 μM Valdecoxib | 25 minutes | To assess the reversible inhibition of platelet Cox-1 activity by Valdecoxib, with an IC50 value of 28 μM | Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14583-8. |
Ovine cyclooxygenase-1 (oCox-1) | 200 μM aspirin and 0–100 μM Valdecoxib | 30 minutes | To evaluate the antagonism of Valdecoxib against the irreversible inactivation of oCox-1 by aspirin, with an EC50 value of 13 μM | Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14583-8. |
R28 cells | 1 and 5 μmol/L | 4 hours | Valdecoxib protects R28 cells from OGD/R injury by decreasing the cell apoptosis rate | Int J Mol Sci. 2022 Oct 26;23(21):12983. |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | C57BL6 wild-type mice | Subcutaneous (P1-P6) and intraperitoneal (P7-P21) | 10 mg/kg | Daily administration from postnatal day 1 (P1) to day 21 (P21) | To evaluate the effect of Valdecoxib on kidney development in mice. Results showed that Valdecoxib caused minimal changes in renal morphology, with kidney weight to body weight ratio similar to controls, and a significant reduction in glomerular diameter, but less severe than other COX-2 inhibitors (e.g., rofecoxib, etoricoxib, and lumiracoxib). | Br J Pharmacol. 2011 Jul;163(5):927-36 |
Mice | MPTP-induced Parkinson's disease model | Oral | 10, 30 or 50 mg/kg | Once daily, starting two weeks before MPTP injection until the end of the experiment | Valdecoxib alleviated the microglial activation, the loss of TH-positive cells and the decrease in open field and vertical activity. COX-2 deficiency attenuated MPTP-induced microglial activation, degeneration of TH-positive cells, and loss of coordination. | J Neuroinflammation. 2006 Mar 27;3:6 |
Sprague-Dawley rats | Retinal ischemia-reperfusion injury model | Intravitreal injection | 5 μM | Single dose, observed for 3 days | Valdecoxib attenuates IRI-induced retinal injury by inhibiting RGC apoptosis | Int J Mol Sci. 2022 Oct 26;23(21):12983. |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00285649 | - | Completed | - | - | |
NCT01221025 | Emergence Delirium ... More >> Postoperative Pain Less << | Phase 4 | Unknown | June 2012 | China, Guangdong ... More >> The First Affiliated Hospital of Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510080 Contact: Haihua Shu, MD; Ph D +86-20-87755766 ext 8273 shuhaihua@gmail.com Less << |
NCT03092193 | Poor Metabolizer Due to Cytoch... More >>rome P450 CYP2C9 Variant Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant Less << | Phase 4 | Recruiting | December 2018 | Brazil ... More >> Bauru School of Dentistry/USP Recruiting Bauru, São Paulo, Brazil, 17012-901 Contact: Adriana M Calvo, PhD 551432358276 birinjela@yahoo.com.br Less << |
NCT00602901 | Subacute Low Back Pain ... More >> Chronic Low Back Pain Less << | Phase 2 | Completed | - | United States, Iowa ... More >> Palmer Center for Chiropractic Research Davenport, Iowa, United States, 52803 The University of Iowa Iowa City, Iowa, United States, 52242 Less << |
NCT00115752 | Pain | Phase 2 | Completed | - | United States, Maryland ... More >> National Institute of Nursing Research (NINR) Bethesda, Maryland, United States, 20892 Less << |
NCT01361789 | Rupture of Anterior Cruciate L... More >>igament Less << | Phase 4 | Completed | - | Norway ... More >> Baerum Hospital Rud, Norway, 1309 Less << |
NCT00285649 | Low Back Pain | Not Applicable | Completed | - | United States, Iowa ... More >> Palmer Center for Chiropractic Research Davenport, Iowa, United States, 52803 Less << |
NCT01541137 | Postoperative Pain | Not Applicable | Completed | - | Finland ... More >> Helsinki University Central Hospital Helsinki, Finland Less << |
NCT00763997 | Platelet Aggregation | Not Applicable | Completed | - | Germany ... More >> BG University Hospital Bergmannsheil GmbH Bochum, Germany, 44789 Less << |
NCT00092339 | Postoperative Pain | Phase 3 | Completed | - | - |
NCT00092300 | Postoperative Pain | Phase 3 | Completed | - | - |
NCT00122096 | Neurosurgery ... More >>Pain Less << | Phase 4 | Completed | - | United States, Washington ... More >> University of Washington Seattle, Washington, United States, 98195 Less << |
NCT00636064 | Pain | Phase 3 | Completed | - | - |
NCT00650624 | Osteoarthritis, Knee | Phase 2 | Completed | - | Japan ... More >> Pfizer Investigational Site Funabashi, Chiba, Japan Pfizer Investigational Site Sakura, Chiba, Japan Pfizer Investigational Site Chikushi-gun, Fukuoka, Japan Pfizer Investigational Site Iizuka, Fukuoka, Japan Pfizer Investigational Site Kurume, Fukuoka, Japan Pfizer Investigational Site Yame, Fukuoka, Japan Pfizer Investigational Site Chitose, Hokkaido, Japan Pfizer Investigational Site Sapporo, Hokkaido, Japan Pfizer Investigational Site Kamakura, Kanagawa, Japan Pfizer Investigational Site Yokohama, Kanagawa, Japan Pfizer Investigational Site Isahaya, Nagasaki, Japan Pfizer Investigational Site Hirakata, Osaka, Japan Pfizer Investigational Site Kanzaki-gun, Saga, Japan Pfizer Investigational Site Karatsu, Saga, Japan Pfizer Investigational Site Ogi-gun, Saga, Japan Pfizer Investigational Site Itabashi-ku, Tokyo, Japan Pfizer Investigational Site Setagaya-ku, Tokyo, Japan Pfizer Investigational Site Shinjuku-Ku, Tokyo, Japan Pfizer Investigational Site Taito-ku, Tokyo, Japan Pfizer Investigational Site Yoyogi Shibuya-ku, Tokyo, Japan Pfizer Investigational Site Saga, Japan Pfizer Investigational Site Tokyo, Japan Less << |
NCT00650039 | Pain | Phase 3 | Completed | - | - |
NCT00649415 | Dysmenorrhea | Phase 4 | Completed | - | Brazil ... More >> Pfizer Investigational Site Salvador, Bahia, Brazil Pfizer Investigational Site Goiania, Goias, Brazil Pfizer Investigational Site Belo Horizonte, Minas Gerais, Brazil, 30130-100 Pfizer Investigational Site Belo Horizonte, Minas Gerais, Brazil, 30130-110 Pfizer Investigational Site Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000 Pfizer Investigational Site Rio De Janeiro, RJ, Brazil, 20551-030 Pfizer Investigational Site Porto Alegre, RS, Brazil Pfizer Investigational Site São Paulo, SP, Brazil Pfizer Investigational Site Sao Paulo, Brazil Pfizer Investigational Site São Paulo, Brazil, 04062-003 Less << |
NCT00650598 | Pain, Postoperative | Phase 4 | Completed | - | Australia, South Australia ... More >> Pfizer Investigational Site Adelaide, South Australia, Australia, SA 5000 Hong Kong Pfizer Investigational Site Hong Kong, Hong Kong Pfizer Investigational Site Shatin, New Territories, Hong Kong Korea, Republic of Pfizer Investigational Site Seoul, Korea, Republic of, 110-744 Pfizer Investigational Site Seoul, Korea, Republic of, 138-736 Pfizer Investigational Site Seoul, Korea, Republic of, 140-757 Pfizer Investigational Site Seoul, Korea, Republic of Malaysia Pfizer Investigational Site Cheras, Kuala Lumpur, Malaysia, 56000 Pfizer Investigational Site Kuala Lumpur, Wilayah Persekutuan, Malaysia, 50586 Pfizer Investigational Site Kuala Lumpur, Wilayah Persekutuan, Malaysia, 59100 New Zealand Pfizer Investigational Site Auckland, New Zealand Pfizer Investigational Site Christchurch, New Zealand Pfizer Investigational Site Wellington, New Zealand Philippines Pfizer Investigational Site Manila, Philippines Pfizer Investigational Site Quezon City, Philippines Pfizer Investigational Site Quezon, Philippines Singapore Pfizer Investigational Site Singapore, Singapore, 529889 Taiwan Pfizer Investigational Site Kaohsiung, Taiwan Pfizer Investigational Site Keelung, Taiwan Pfizer Investigational Site Taipei, Taiwan Thailand Pfizer Investigational Site Bangkok, Thailand, 10330 Pfizer Investigational Site Bangkok, Thailand, 10400 Pfizer Investigational Site Bangkok, Thailand, 10700 Pfizer Investigational Site Bangkok, Thailand Less << |
NCT00647829 | Pharyngitis | Phase 3 | Completed | - | United States, Connecticut ... More >> Pfizer Investigational Site Storrs, Connecticut, United States, 06269-2011 United States, Florida Pfizer Investigational Site Boca Raton, Florida, United States, 33433 Less << |
NCT00260325 | Pain Hyperalg... More >>esia Less << | Phase 4 | Completed | - | United States, Pennsylvania ... More >> Penn State University College of Medicine Hershey, Pennsylvania, United States, 17033 Less << |
NCT00653354 | Pain, Post-surgical | Phase 3 | Completed | - | United States, Arizona ... More >> Pfizer Investigational Site Phoenix, Arizona, United States, 85015 Pfizer Investigational Site Phoenix, Arizona, United States, 85016 Pfizer Investigational Site Phoenix, Arizona, United States, 85020 Pfizer Investigational Site Phoenix, Arizona, United States, 85032 Pfizer Investigational Site Tempe, Arizona, United States, 85281 United States, California Pfizer Investigational Site Anaheim, California, United States, 92701 Pfizer Investigational Site Chula Vista, California, United States, 91911 Pfizer Investigational Site San Diego, California, United States, 92114 Pfizer Investigational Site Santa Ana, California, United States, 92701 Pfizer Investigational Site Tustin, California, United States, 92780 United States, Kentucky Pfizer Investigational Site Lexington, Kentucky, United States, 40504 Pfizer Investigational Site Lexington, Kentucky, United States, 40509 Pfizer Investigational Site Lexington, Kentucky, United States, 40515 United States, Pennsylvania Pfizer Investigational Site Altoona, Pennsylvania, United States, 16602 Pfizer Investigational Site Duncansville, Pennsylvania, United States, 16635 United States, Tennessee Pfizer Investigational Site Johnson City, Tennessee, United States, 37601 Pfizer Investigational Site Johnson City, Tennessee, United States, 37604 United States, Texas Pfizer Investigational Site San Antonio, Texas, United States, 78229 Pfizer Investigational Site San Antonio, Texas, United States, 78240 United States, Utah Pfizer Investigational Site Salt Lake City, Utah, United States, 84117 Pfizer Investigational Site Salt Lake City, Utah, United States, 84123 Less << |
NCT00648258 | Osteoarthritis | Phase 3 | Completed | - | Taiwan ... More >> Pfizer Investigational Site Kweishan, Taoyuan, Taiwan Pfizer Investigational Site Kaohsiung, Taiwan Pfizer Investigational Site Taichung, Taiwan Pfizer Investigational Site Taipei, Taiwan Less << |
NCT00021996 | Pain Unspecif... More >>ied Adult Solid Tumor, Protocol Specific Less << | Not Applicable | Completed | - | United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less << |
NCT00651300 | Pain | Phase 3 | Terminated(See Detailed Descri... More >>ption field.) Less << | - | Australia, New South Wales ... More >> Pfizer Investigational Site Port Macquarie, New South Wales, Australia Pfizer Investigational Site Randwick, New South Wales, Australia, 2031 Pfizer Investigational Site Westmead, New South Wales, Australia, 2145 Australia, Queensland Pfizer Investigational Site Coopers Plain, Queensland, Australia, 4108 Pfizer Investigational Site Townsville, Queensland, Australia, 4814 Australia, Victoria Pfizer Investigational Site Heidelberg, Victoria, Australia, 3084 Pfizer Investigational Site Prahran, Victoria, Australia, 3181 Australia, Western Australia Pfizer Investigational Site Perth, Western Australia, Australia, 6847 Less << |
NCT00661635 | Laparoscopic Cholecystectomy ... More >> Pain Less << | Phase 3 | Completed | - | - |
NCT00652808 | Osteoarthritis ... More >> Knee Less << | Phase 3 | Completed | - | Korea, Republic of ... More >> Pfizer Investigational Site Anyang, Korea, Republic of, 431-070 Pfizer Investigational Site Gwangju, Korea, Republic of, 501-757 Pfizer Investigational Site Incheon, Korea, Republic of, 405-760 Pfizer Investigational Site Pusan, Korea, Republic of, 602-739 Pfizer Investigational Site Seoul, Korea, Republic of, 110-744 Pfizer Investigational Site Seoul, Korea, Republic of, 137-701 Pfizer Investigational Site Seoul, Korea, Republic of, 138-736 Pfizer Investigational Site Seoul, Korea, Republic of, 152-703 Less << |
NCT00671320 | Pain Sprains ... More >>and Strains Sprain Less << | Phase 4 | Completed | - | Argentina ... More >> Pfizer Investigational Site Avellaneda, Buenos Aires, Argentina, 1872 Pfizer Investigational Site San Isidro, Buenos Aires, Argentina, 1642 Pfizer Investigational Site Buenos Aires, Argentina Chile Pfizer Investigational Site Santiago, RM, Chile Pfizer Investigational Site Santiago, Chile Colombia Pfizer Investigational Site Medellin, Antioquia, Colombia, (574) 5141516 Pfizer Investigational Site Bogota, Cundinamarca, Colombia, (57) 310-2322198 Pfizer Investigational Site Bogota, Cundinamarca, Colombia, (57) 310-8849622 Pfizer Investigational Site Bogota, Cundinarmarca, Colombia, (571) 6 164278 Pfizer Investigational Site Bucaramanga, Santander, Colombia, (577) 6 395409 Pfizer Investigational Site Cali, Valle del Cauca, Colombia, (57) 315-5410469 Pfizer Investigational Site Calli, Valle del Cauca, Colombia, (57) 310-8259712 Mexico Pfizer Investigational Site Monterrey, Nuevo Leon, Mexico, 64460 Peru Pfizer Investigational Site Lima, Peru, 27 Pfizer Investigational Site Lima, Peru Less << |
NCT00657449 | Acute Pain | Phase 4 | Terminated(See termination rea... More >>son in detailed description.) Less << | - | Brazil ... More >> Instituto Ortopedico de Goiania Goiania, Goias, Brazil, 74210-030 Centro de Traumatologia e Ortopedia Goiania, Goiás, Brazil Hospital Mãe de Deus Porto Alegre, RIO Grande DO SUL, Brazil, 90880480 Hospital Sao Zacarias Rio de Janeiro, RJ, Brazil Grupo Hospitalar Conceiçao Porto Alegre, RS, Brazil, 91350200 Hospital Geral do Grajau São Paulo, SP, Brazil, 04822-320 Unifesp - Hsp São Paulo, Brazil, 04063003 SECONCI São Paulo, Brazil, 05001000 Less << |
NCT00683137 | Pain Hallux V... More >>algus Less << | Phase 3 | Completed | - | - |
NCT00649610 | Low Back Pain | Phase 4 | Completed | - | Argentina ... More >> Pfizer Investigational Site Bs. As., Argentina Pfizer Investigational Site Buenos Aires, Argentina, C1221ACI Brazil Pfizer Investigational Site Goiania, Goias, Brazil, 74085-450 Pfizer Investigational Site Curitiba, Parana, Brazil, 80430-210 Pfizer Investigational Site Curitiba, PR, Brazil Pfizer Investigational Site Petropolis, Rio de Janeiro, Brazil, 25620-040 Pfizer Investigational Site Sao Paulo, SP, Brazil, 04023-900 Pfizer Investigational Site Sao Paulo, SP, Brazil, 04029-000 Pfizer Investigational Site Sao Paulo, SP, Brazil, 05403-012 Pfizer Investigational Site Sao Paulo, Brazil, 05001-000 Chile Pfizer Investigational Site Santiago, Chile Colombia Pfizer Investigational Site Bogota, D.c., Colombia Pfizer Investigational Site Bogota D.c, Colombia Pfizer Investigational Site Cali-valle, Colombia Costa Rica Pfizer Investigational Site Cartago City, Cartago, Costa Rica, 7051 Pfizer Investigational Site Hatillo, San Jose, Costa Rica, 476-1002 Ecuador Pfizer Investigational Site Quito, Pichincha, Ecuador Mexico Pfizer Investigational Site Toluca, Edo. de Mexico, Mexico, 50080 Pfizer Investigational Site Zapopan, Jalisco, Mexico, 45040 Pfizer Investigational Site Zapopan, Jalisco, Mexico, 45200 Pfizer Investigational Site Puebla, Mexico, 72000 Pfizer Investigational Site Puebla, Mexico, 72070 Pfizer Investigational Site Puebla, Mexico, 72410 Peru Pfizer Investigational Site Lima, Peru, LIMA 11 Pfizer Investigational Site Lima, Peru, LIMA 27 Venezuela Pfizer Investigational Site Caracas, DF, Venezuela, 1020 Pfizer Investigational Site Caracas, DF, Venezuela, 1051 Pfizer Investigational Site Caracas, DF, Venezuela, 1070 Pfizer Investigational Site Caracas, Venezuela Less << |
NCT00419549 | ERCP Pancreat... More >>itis Less << | Phase 2 Phase 3 | Terminated(Because one of the ... More >>drugs Valdecoxib was withdrawn due to safety concerns.) Less << | - | India ... More >> All India Institute of Medical Sciences New Delhi, India Less << |
NCT00660855 | Pain, Post Surgical | Phase 4 | Terminated(See Detailed Descri... More >>ption.) Less << | - | Argentina ... More >> Pfizer Investigational Site Buenos Aires, Argentina, C1230AAW Pfizer Investigational Site Buenos Aires, Argentina, C1280AEB Less << |
NCT00650455 | Arthritis, Rheumatoid | Phase 4 | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.18mL 0.64mL 0.32mL |
15.91mL 3.18mL 1.59mL |
31.81mL 6.36mL 3.18mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|